AVANIR Plans Commercial Launch of Nuedexta; Drug’s Potential to be Proven in the Market
  • Stock Alert for Achillion Pharmaceuticals Inc. (ACHN)
  • " />

    Stock Alert for Avanir Pharmaceuticals (AVNR)

    Avanir Pharmaceuticals Inc. (AVNR) is a pharmaceutical company focused on developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. In October 2010, the U.S. Food and Drug Administration (FDA) approved NUEDEXTA, a unique proprietary combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA). NUEDEXTA has also successfully completed a phase III trial for the treatment of patients with diabetic peripheral neuropathic pain (DPN pain). In addition to its focus on products for the central nervous system, AVNR also has a number of partnered programs in other therapeutic areas. Its first commercialized product, docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the FDA. In 2008, the Company out-licensed all of its monoclonal antibodies and it remains eligible to receive milestone payments and royalties related to the sale of these assets.

    AVNR was incorporated in August 1998 and is headquartered in Aliso Viejo, California.

    Share Statistics (16-May-11) FY 












    Symbol AVNR Revenue, $Mn 4.18 2.90 -30.6% 1.48 1.82 23.0%
    Current price $3.97 Gross marg. 97.8% 93.1% -4.8% 100.0% 100.0%
    52wk Range: $1.31-$5.80 Oper. margin -935.8% -666.4%
    Avg Vol (3m): 5,365,980 Net margin -526.3% -929.7% 76.6% -325.7% -665.4% 104.3%
    Market Cap. 482.64M
    Shares Outstanding 121.57M EPS, $ -0.28 -0.30 7.1% -0.06 -0.11 83.3%

    Source: Reuters.com, SEC Filings.

    Investment Highlights
    AVNR saw strength on Monday, with shares gaining almost 3% to close the session at $3.97, ahead of a presentation at this year’s meeting of the American Psychiatric Association (APA). About 16 million shares have traded hands during the session, versus the 10-day average volume of 7.92 million. The Company on Monday said data from a number of clinical research activities will be highlighted at the meeting, which will be held in Honolulu, Hawaii.

    AVNR recently announced its financial results for the second quarter of fiscal 2011. The Company reported total net revenue of $1.4 million for the three months that ended March 31, 2011, compared with $1 million for the comparable quarter in 2010.  Total operating expenses came in at $15.8 million in the second quarter of fiscal 2011, compared with $7.4 million in the same period a year ago. AVNR posted a net loss of $14.5 million, or $0.12 a share, compared to a net loss of $6.4 million, or $(0.08) a year ago. Analysts, on average, were expecting a loss of $(0.15) a share on revenue of $2.4 million, according to a poll by FactSet.

    AVNR reported NUEDEXTA gross and net revenue of $505,000 and $462,000, respectively, for the quarter. The total NUEDEXTA net shipments for the quarter were $3.1 million while net deferred revenue was $2.6 million. NUEDEXTA was launched in February this year.

    “With the mid-February launch of NUEDEXTA, the only FDA approved treatment for pseudobulbar affect, we have become a commercial stage biopharmaceutical company,” commented AVNR president and CEO Keith A. Katkin.  “I believe we are off to a promising start with over 1,000 new prescriptions through the end of March, representing the first seven weeks of launch. With a strong balance sheet, dedicated and talented employees, and plans for further clinical development, I believe Avanir is poised for a successful fiscal 2011.”

    As of March 31, 2011, the Company had cash, cash equivalents and investments in securities totaling $105.1 million, including cash and cash equivalents of $103.0 million and restricted investments in securities of $2.1 million.

    AVNR also recently announced the PRISM patient registry, the first patient registry to further quantify the prevalence and quality of life impact of pseudobulbar affect (PBA) in patients with a variety of underlying neurologic conditions. The Company said the PRISM registry aims to define the prevalence of PBA in patients with the associated underlying neurologic conditions of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson’s disease, stroke, traumatic brain injury (TBI) and Alzheimer’s disease. AVNR expects to recruit 10,000 patients into the registry across approximately 500 sites in the United States.

    Visit AVNR at www.avanir.com

    Financial Strength (16-May-2011) Company Industry Sector S&P 500
    Quick Ratio (MRQ) 18.20 1.91 1.86 0.69
    Current Ratio (MRQ) 18.28 2.30 2.29 1.02
    LT Debt to Equity (MRQ) 0.00 9.09 20.26 151.16
    Total Debt to Equity (MRQ) 0.00 11.28 24.93 198.11
    Interest Coverage (TTM) 0.18 1.72 17.31

    Source: Reuters.com, SEC Filings.

    Analyst Consensus

    This is the consensus forecast among four polled investment analysts. Against the Avanir Pharmaceuticals Inc company.

    Analyst Detail Buy Outperform Hold Underperform Sell No Opinion
    Latest 4 0 0 0 0 0
    4 weeks ago 4 0 0 0 0 0
    2 months ago 4 0 0 0 0 0
    3 months ago 3 0 0 0 0 0
    Last year 2 0 0 0 0 0

    The four analysts offering 12-month price targets for AVNR have a median target of 11.50, with a high estimate of 15.00 and a low estimate of 6.00. The median estimate represents a 197.93% increase from the last price of 3.86.

    Source: markets.ft.com

    Consensus Estimates Analysis

    # of Estimates Mean High Low 1 Year Ago
    SALES (in millions)
    Quarter Ending Jun-11 3 5.25 10.75 2.40 2.30
    Quarter Ending Sep-11 3 8.05 16.75 3.40 4.50
    Year Ending Sep-11 3 17.07 33.07 9.00 60.45
    Year Ending Sep-12 3 68.05 111.00 38.10 170.06
    EARNINGS (per share)
    Quarter Ending Jun-11 3 -0.13 -0.11 -0.15 -0.12
    Quarter Ending Sep-11 3 -0.13 -0.09 -0.15 -0.13
    Year Ending Sep-11 3 -0.49 -0.42 -0.54 -0.14
    Year Ending Sep-12 3 -0.37 -0.05 -0.67 -0.26

    Technical Analysis

    Source: http://stockcharts.com

    AVNR is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.

    The MACD for AVNR currently indicates a strong bearish signal for two reasons. First, the MACD is below the signal line, a 9-day moving average. Second, the MACD is below the critical level of 0, which implies that the underlying moving averages are trending lower.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    May16-2011 symbol Share, $ $ Mn 2011 2012 2011 2012
    Bristol-Myers Squibb Company BMY 28.79 49.12B 13.09 13.84 2.40 2.69
    GlaxoSmithKline plc GSK 43.68 111.10B 11.81 10.95 2.47 2.37
    Eli Lilly & Co. LLY 39.15 43.53B 9.17 10.55 1.85 1.98
    Drug Manufacturers – Other Median 19.67 n/a 5.11 n/a
    Avanir Pharmaceuticals Inc. AVNR 3.97 482.64M 44.11 12.91 4.14

    Source: Thomson Financial

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

    Leave a Reply

    Your email address will not be published. Required fields are marked *